CBD13 + THC9

CBD13 + THC9 is a combination drug formulation containing cannabidiol (CBD) at a concentration of 13% and delta-9-tetrahydrocannabinol (THC) at 9%. Both are major cannabinoids derived from the Cannabis sativa plant. This specific ratio has been studied for its therapeutic effects, particularly in neurological conditions such as multiple sclerosis (MS). The mechanism of action involves modulation of the endocannabinoid system through partial agonism at cannabinoid receptors CB1 and CB2. THC primarily acts as a partial agonist at both receptors, leading to psychoactive and muscle relaxant effects, while CBD modulates these actions by acting as an allosteric modulator and influencing other targets such as serotonin receptors. The combination has demonstrated efficacy in reducing muscle spasticity and improving disability progression rates in MS patients[2][1]. Additionally, it exhibits anti-inflammatory properties by attenuating neuroinflammation and altering gut microbiota composition[1]. Drug-drug interactions are significant due to shared metabolism via cytochrome P450 enzymes (notably CYP3A4, CYP2C9, CYP2C19), which can affect plasma levels of co-administered medications[5][6][7].